How it works, simply
It was designed from part of erythropoietin to explore tissue-protective signaling without its red-blood-cell-producing effect.
What the evidence tells us
A small randomized trial in people with sarcoidosis-associated small-fiber nerve loss reported changes in nerve-fiber measures. The population, endpoints and short follow-up limit what can be inferred about other neuropathies or long-term benefit.
Small studies in sarcoidosis-related nerve damage found signals worth further study; they do not establish broad nerve-repair benefits.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This guide does not establish a safe dose, interaction profile or long-term safety for self-use. Effects reported for one route or formulation may not apply to another.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Derived from erythropoietin helices and designed to engage tissue-protective signaling without erythropoiesis.
Sponsor or developer: Araim Pharmaceuticals
Studied or labeled topics: Small-fiber neuropathy, Inflammatory conditions
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- Cibinetide trial in sarcoidosis-associated small-fiber loss (2017) ↗ · Research paper · 2017-05-01
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (listed study only). A wording update is not a new clinical review.